prospect
studi
perform
evalu
compar
perform
multiplex
pcr
seeplex
assay
ii
assay
may
april
total
respiratori
sampl
collect
okinawa
japan
multipl
respiratori
pathogen
detect
patient
posit
result
preval
pathogen
influenza
viru
respiratori
syncyti
viru
b
despit
minor
differ
capabl
seeplex
assay
ii
assay
easili
implement
diagnost
research
laboratori
optim
detect
manag
respiratori
pathogen
induc
diseas
diagnost
decis
acut
upper
respiratori
tract
infect
increasingli
reli
molecular
test
method
multipl
studi
shown
util
multiplex
pcr
method
abl
detect
differenti
pathogen
one
assay
addit
earli
diagnosi
respiratori
pathogen
known
valuabl
clinic
manag
improv
patient
outcom
reduc
complic
time
spent
hospit
antibiot
use
unnecessari
laboratori
test
howev
report
evalu
compar
util
newli
develop
assay
japan
aim
studi
evalu
compar
perform
multiplex
pcr
seeplex
assay
ii
assay
diagnost
aid
current
ongo
larger
comprehens
studi
upper
respiratori
infect
okinawa
japan
sampl
collect
prospect
nonselect
manner
patient
within
okinawa
japan
may
april
total
respiratori
sampl
nasopharyng
swab
sputum
bronchoalveolar
lavag
fluid
sampl
collect
uniqu
patient
acut
respiratori
symptom
eg
cough
sputum
visit
admit
univers
ryukyu
hospit
affili
hospit
patient
identifi
inform
remov
protect
patient
confidenti
institut
ethic
committe
univers
ryukyu
approv
studi
upon
receipt
patient
sampl
store
c
process
nucleic
acid
extract
sampl
within
h
use
vrd
geneal
biotechnolog
co
ltd
seoul
south
korea
accord
manufactur
instruct
final
elut
volum
ml
sampl
test
use
seeplex
pneumobact
ace
detect
seeplex
onestep
ace
detect
dual
prime
oligonucleotid
base
multiplex
assay
maxim
pcr
sensit
specif
inhibit
nonspecif
prime
well
ii
detect
ii
detect
kit
seegen
inc
seoul
south
korea
util
multiplex
realtim
pcr
base
tag
oligonucleotid
cleavag
extens
technolog
affect
sequenc
variat
observ
among
dna
guarante
consist
melt
curv
analysi
introduc
two
compon
pitcher
catcher
accomplish
uniqu
signal
gener
realtim
accord
includ
user
manual
seegen
inc
pcr
product
seeplex
assay
detect
use
microchip
electrophoresi
multina
system
shimadzu
corp
kyoto
japan
analyz
sampl
viral
infect
use
assay
cdna
first
synthes
extract
nucleic
acid
use
cdna
synthesi
premix
includ
seegen
inc
assay
analyz
realtim
use
realtim
pcr
system
biorad
laboratori
inc
berkley
ca
usa
target
amplif
pcr
perform
presenc
posit
neg
control
ensur
qualiti
result
pathogen
detect
patient
singl
pathogen
found
wherea
multipl
pathogen
found
total
patient
posit
result
fortyseven
patient
multipl
pathogen
detect
seeplex
wherea
fifteen
patient
multipl
pathogen
detect
influenza
respiratori
syncyti
viru
b
rsv
b
commonli
detect
viral
pathogen
respect
pneumonia
h
influenza
commonli
detect
bacteria
pathogen
respect
sampl
test
posit
b
parapertussi
coronaviru
human
bocaviru
parainfluenza
viru
statist
analysi
use
interrat
agreement
two
assay
show
high
agreement
rate
rang
agreement
kappa
valu
rang
shown
tabl
pneumonia
h
influenza
coronaviru
includ
seeplex
assay
b
parapertussi
coronaviru
coronaviru
includ
assay
kappa
score
could
calcul
pathogen
without
posit
result
without
kappa
score
exclud
tabl
nevertheless
high
degre
correl
found
two
assay
agreement
highest
pneumonia
b
pertussi
metapneumoviru
respiratori
syncyti
viru
low
kappa
valu
indic
poor
agreement
ie
calcul
adenoviru
human
enteroviru
like
reflect
differ
genet
target
use
among
two
assay
exampl
addit
adenoviru
type
detect
seeplex
ii
kit
also
detect
type
moreov
ii
kit
detect
multipl
strain
coxsackieviru
echoviru
human
enteroviru
accord
includ
user
manual
seegen
inc
assay
method
consid
use
diagnost
laboratori
detect
respiratori
pathogen
although
workload
assay
lighter
compar
cultur
detect
downfal
exist
instanc
seeplex
assay
requir
postamplif
detect
nucleic
acid
extract
amplif
furthermor
postamplif
detect
seeplex
result
subject
interpret
creat
potenti
fals
posit
result
contrast
assay
requir
postamplif
detect
therefor
runtim
reduc
realtim
detect
also
elimin
manipul
amplifi
product
minim
problem
associ
amplicon
contamin
carryov
still
ii
kit
measur
intern
threshold
set
manufactur
could
potenti
creat
fals
neg
result
howev
despit
minor
shortcom
sensit
specif
compar
pcr
detect
kit
remain
high
evalu
bacteria
viral
cultur
kim
et
al
specif
state
seeplex
kit
superior
luminex
xtag
respiratori
viral
panel
time
save
less
laborintens
limit
investig
first
compar
larg
enough
volum
respiratori
pathogen
except
influenza
rsv
b
rhinoviru
calcul
kappa
score
depend
confid
interv
limit
sampl
size
affect
power
studi
inadequ
number
posit
result
limit
accuraci
kappa
score
second
patient
background
symptomatolog
beyond
acut
respiratori
symptom
collect
part
studi
result
predict
valu
test
could
calcul
addit
cultur
use
compar
result
gener
sensit
specif
howev
mani
report
previous
shown
pcr
detect
pathogen
greater
sensit
specif
cultur
last
sampl
collect
sequenti
therefor
repres
local
epidemiolog
conclus
assay
method
correl
well
provid
use
method
detect
common
respiratori
pathogen
addit
multiplex
design
assay
allow
broad
rang
etiolog
investig
simultan
